By Zenith Pharmaceuticals Ltd.
Weight: 400 mg
Unit Price: 14.06
Last Updated: 2019-09-03 08:36:36
Gatifloxacin is indicated in the following infections:
Gatifloxacin is a fluoroquinolone antibacterial which acts by inhibiting DNA synthesis in susceptible organisms via inhibition of both DNA gyrase (essential for bacterial reproduction) and topoisomerase IV (essential during bacterial cell division).
Acute Bacterial Exacerbation of Chronic Bronchitis: 400 mg 5 days
Acute Sinusitis: 400 mg 10 days
Community-acquired Pneumonia: 400 mg 7-14 days
Uncomplicated Skin and Skin Structure Infections: 400 mg 7-10 days
Uncomplicated Urinary Tract Infections: 400 mg Single Dose or 200 mg 3 days
Complicated Urinary Tract Infections: 400 mg 7-10 days
Acute Pyelonephritis: 400 mg 7-10 days
Uncomplicated Urethral Gonnorrhea in Men: 400 mg Single dose
Gatifloxacin is generally well tolerated. The most common side effects that can occur while taking this drug are usually mild and include nausea, vomiting, stomach pain, diarrhea, dizziness,and headache .
Gatifloxacin should be administered with caution in the presence of renal insufficiency.
Pregnancy: Gatifloxacin should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Lactation: It is not known whether Gatifloxacin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when gatifloxacin is administered to a nursing woman.
Gatifloxacin exhibits a low potential for acute toxicity in animal studies. In the event of acute oral overdose, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed (including ECG monitoring) and given symptomatic and supportive treatment. Adequate hydration should be maintained.
Gatifloxacin is contraindicated in patients with a history of hypersensitivity of Gatifloxacin, quinolone antimicrobial agents, or any other components of this product.
Gatifloxacin can be administered without regard to food.
Renal Impaired patient:
Pediatric use: The safety and effectiveness of Gatifloxacinacin in pediatric populations (<18 years of age) have not been established.